Answer
It may increase metformin exposure by inhibiting MATE transporters. Clinicians should monitor for metformin-related adverse effects and review treatment if necessary.
Sources for this answer
- Evrysdi 0.75 mg/mL powder for oral solutionemc · SmPC Current selected SmPC · Version 12
- Evrysdi 5 mg film‑coated tabletsemc · SmPC Current selected SmPC · Version 1